Therapy Development - Classes of Therapies

Following are the various treatments for Parkinson’s disease currently being studied in the scientific community. Clicking on the links (blue text) will take you to pages that summarize how each specific therapy works and is administered, as well as its potential benefits and risks.
A2A  adenosine receptor agonist
A2A  adenosine receptor antagonist
ACE Inhibitor
Adenosine receptor agonist
Adenosine receptor antagonist
Adrenergic receptor antagonist
Adult stem cells	See: Cell transplantation
Alpha-2 adrenergic antagonist
Alpha-synuclein inhibitor	See: Gene therapy
AMPA Receptor (glutamate) antagonist	See: Glutamate blocker
Anticonvulsant
Antineurodegenerative agent	See: Neuroprotective factor
Anti Inflammatory Agent
Ayurvedic
Calcium channel modulator
Cell Transplantation
Dopamine D1 receptor agonists Dopamine D1  agonist Dopamine D2  agonist Dopamine D2 partial agonist/5HT1A agonist	See: Dopamine agonist
Dopamine agonist
Embryonic stem cells	See: Cell transplantation
Estrogen
5HT2A/C receptor inverse agonist	See: Serotonin receptor blocker
GAD gene therapy	See: Gene therapy
Gene therapy
Glutamate blocker
Glycosphingolipid
Hedgehog pathway agonist
Kinase apoptosis inhibitor	See: Kinases inhibitor
Kinases inhibitor
Levodopa
Medicinal plant
Monoamine oxidase type B (MAO-B) inhibitor
Monoamine reuptake blocker
Neuroimmunophilin ligand
Neuroprotective factor
Nerve Growth Factor
NMDA agonist
NSAID	See: Anti-Inflammatory Agent
PARP Inhibitor
Retinal pigmented epithelial (RPE) cell	See: Cell transplantation
Rnai  (RNA interference) technology	See: Gene therapy
Selective agonist of serotonin 5-HT1A receptors	See: Serotonin receptor agonist
Serotonin receptor agonist
Serotonin receptor blocker
Small molecule Hedgehog pathway agonist	See : Hedgehog pathway agonist
Sodium channel blocker
Stem cells	See: Cell transplantation